AstraZeneca solar panel field at its Macclesfield location in the UK.

As­traZeneca ad­vances net-ze­ro car­bon goals, adding Hon­ey­well deal and out­sider over­sight among new ESG ef­forts

Just a few years ago, the phar­ma in­dus­try was la­beled as a big-time car­bon pol­luter in a study that showed green­house gas emis­sions that were 55% high­er than the au­to in­dus­try. The study and me­dia re­ports that fol­lowed ex­pressed some shock amid sur­pris­ing­ly scant at­ten­tion paid to the in­dus­try by en­vi­ron­men­tal watch­ers.

Since then, how­ev­er, phar­ma com­pa­nies have tak­en up the chal­lenge — in­clud­ing ef­forts by many to dri­ve to net-ze­ro emis­sion goals. As­traZeneca, along with No­var­tis and Mer­ck, is lead­ing the time race in the in­dus­try, set­ting com­pa­ny goals for 2025, fol­lowed by a larg­er group of phar­mas aim­ing for 2030. ESG track­er SP­Glob­al notes J&J, Pfiz­er, Glax­o­SmithK­line, Sanofi and BioN­Tech among the lat­ter group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.